Earnings reaction and recent share performance

RadNet (RDNT) recently reported second quarter and first half 2026 results, with higher revenue alongside lower quarterly net income and a larger loss for the six month period compared with a year earlier.

Over the past month, the stock has gained 24.3%. Over the past 3 months it is up 45.7%, while the 1 year total return stands at 13.2%. Year to date, the share price has risen 7.6%.

The latest earnings release appears to be the main catalyst for RadNet’s recent move, with the stock showing strong short term share price momentum while longer term total shareholder returns remain substantial on a multi year view.

If you are comparing RadNet’s recent move with other opportunities in the sector, it can help to widen the lens and review a broader set of healthcare imaging and diagnostics peers through our screener of 44 healthcare AI stocks

RadNet’s imaging and digital health business looks substantial, and the recent share price jump underlines that. The key issue now is whether that growth story is already fully reflected in today’s valuation.

Most Popular Narrative: 17.8% Undervalued

RadNet’s most followed valuation narrative points to a fair value of $92.88 versus the latest close of $76.35, which puts a spotlight on what needs to go right in the years ahead.

Ongoing investments in AI-powered imaging solutions (e.g., DeepHealth, See-Mode, iCAD) are materially increasing center throughput, boosting capacity utilization, and driving more high-margin advanced procedures, directly enhancing both revenue growth and EBITDA margins as adoption scales through 2026.

Curious what sits behind that valuation gap for RadNet? The narrative leans heavily on rising revenue, a sharp swing into profitability, and richer margins. The exact hurdles and timeframes are all laid out there.

Result: Fair Value of $92.88 (UNDERVALUED)

However, RadNet’s narrative could still be tested if heavy AI and digital health spending strains cash flows, or if reimbursement terms and payer contracts turn less favorable.

Next Steps

If this RadNet story feels finely balanced between risk and reward, now is the time to review the details and test the assumptions yourself. To weigh both sides of the argument in one place, start with the 3 key rewards and 2 important warning signs.

Looking for more RadNet investment ideas?

If RadNet has caught your attention, do not stop there. Use the Simply Wall Street Screener to quickly surface fresh ideas that fit your style and goals.

• Target potential value opportunities by reviewing companies highlighted in the 50 high quality undervalued stocks that may currently trade below their assessed worth.
• Prioritize income and resilience by examining stocks in the 10 dividend fortresses that pair higher yields with stability-focused fundamentals.
• Focus on financial strength by scanning the solid balance sheet and fundamentals stocks screener (50 results) for companies with sturdier balance sheets and underlying fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.